Anti-Hu CD69 Alexa Fluor® 647

Anti-Hu CD69 Alexa Fluor<sup>®</sup> 647
Regulatory status
RUO
Antigen
CD69
Clone
FN50
Format
Alexa Fluor® 647
Reactivity
Human
Application
Excitation laser
red (633 nm)
Variant
100 tests
A6-552-T100
In stock
242.00 USD

25 tests
A6-552-T025
Delivery 1 week
121.00 USD
Variant
100 tests
A6-552-T100
In stock
242.00 USD

25 tests
A6-552-T025
Delivery 1 week
121.00 USD
Product details
Description
Images
References
SDS download
Isotype
Mouse IgG1
Specificity
The mouse monoclonal antibody FN50 recognizes an extracellular epitope of CD69, an lymphocyte early activation marker.
Workshop
HLDA IV: WS Code A 91
Application
Application details
Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Reactivity
Human
Immunogen
anti-µ-stimulated human B lymphocytes
Preparation
Purified antibody is conjugated with Alexa Fluor® 647 NHS ester under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Licence note
Alexa Fluor®, Pacific Blue™ and Pacific Orange™ are registered trademarks of Life Technologies Corporation.
Licence label
This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.
Other names
EA1, AIM, MLR-3, CLEC2C, GP32/28, BL-AC/P26
Antigen description
CD69 (C-type lectin domain family 2 C, CLEC2C, also known as AIM) is one of the earliest inducible cell surface molecules acquired during leukocyte activation. This glycoprotein serves as a lectin-type receptor in lymphocytes, NK cells and platelets; it is involved in lymphocyte proliferation. CD69 expression is counteracted on T cells in the AIDS stage of HIV infection, and may be also predictive for clinical response to chemoimmunotherapy.
Entrez Gene ID 969
UniProt ID Q07108
A6-552_FC_Profil Značení
Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human CD69 (FN50) Alexa Fluor® 647 antibody (4 μl reagent / 100 μl of peripheral whole blood).
A6-552_FC_Histogram
Separation of human thrombocytes (red-filled) from CD69 negative lymphocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human CD69 (FN50) Alexa Fluor® 647 antibody (4 μl reagent / 100 μl of peripheral whole blood).

General references:

Konjević G, Jović V, Vuletić A, Radulović S, Jelić S, Spuzić I: CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma. Eur J Clin Invest. 2007 Nov;37(11):887-96.
PubMed
Pitsios C, Dimitrakopoulou A, Tsalimalma K, Kordossis T, Choremi-Papadopoulou H: Expression of CD69 on T-cell subsets in HIV-1 disease. Scand J Clin Lab Invest. 2008;68(3):233-41.
PubMed
Nielsen SD, Afzelius P, Ersbøll AK, Nielsen JO, Hansen JE: Expression of the activation antigen CD69 predicts functionality of in vitro expanded peripheral blood mononuclear cells (PBMC) from healthy donors and HIV-infected patients. Clin Exp Immunol. 1998 Oct;114(1):66-72.
PubMed
López-Cabrera M, Santis AG, Fernández-Ruiz E, Blacher R, Esch F, Sánchez-Mateos P, Sánchez-Madrid F: Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med. 1993 Aug 1;178(2):537-47.
PubMed

Product specific references:

Hrdinka M, Dráber P, Stepánek O, Ormsby T, Otáhal P, Angelisová P, Brdicka T, Paces J, Horejsí V, Drbal K: PRR7 is a transmembrane adaptor protein expressed in activated T cells involved in regulation of T cell receptor signaling and apoptosis. J Biol Chem. 2011 Jun 3;286(22):19617-29.
PubMed
Ohradanova-Repic A, Machacek C, Charvet C, Lager F, Le Roux D, Platzer R, Leksa V, Mitulovic G, Burkard TR, Zlabinger GJ, Fischer MB, Feuillet V, Renault G, Blüml S, Benko M, Suchanek M, Huppa JB, Matsuyama T, Cavaco-Paulo A, Bismuth G, Stockinger H: Extracellular Purine Metabolism Is the Switchboard of Immunosuppressive Macrophages and a Novel Target to Treat Diseases With Macrophage Imbalances. Front Immunol. 2018 Apr 27;9:852.
PubMed
Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989); p. 293.
Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuertbauer E, Howorka S, Hinterberger M, Stockinger H, Schütz GJ: Single-molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement. Int Immunol. 2007 May;19(5):675-84.
PubMed
Tomescu C, Chehimi J, Maino VC, Montaner LJ: NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells. J Immunol. 2007 Aug 15;179(4):2097-104.
PubMed
Quardokus EM, Saunders DC, McDonough E, Hickey JW, Werlein C, Surrette C, Rajbhandari P, Martinez Casals A, Tian H, Lowery L, Neumann EK, Björklund F, Neelakantan TV, Croteau J, Wiblin AE, Fisher J, Livengood AJ, Dowell KG, Silverstein JC, Spraggins JM, Pryhuber GS, Deutsch G, Ginty F, Nolan GP, Melov S, Jonigk D, Caldwell MA, Vlachos IS, Mueller W, Gehlenborg N, Stockwell BR, Lundberg E, Snyder MP, Germain RN, Camarillo JM, Kelleher NL, Börner K, Radtke AJ: Organ mapping antibody panels: a community resource for standardized multiplexed tissue imaging. Nat Methods 2023 Aug;20(8):1174-1178. doi: 10.1038/s41592-023-01846-7.
PubMed
Variant
100 tests
A6-552-T100
In stock
242.00 USD

25 tests
A6-552-T025
Delivery 1 week
121.00 USD
Variant
100 tests
A6-552-T100
In stock
242.00 USD

25 tests
A6-552-T025
Delivery 1 week
121.00 USD

Related products

-134%
Reg. statusCE IVD
ApplicationFC
100 ml
220.00 USD
-134%
CloneMOPC-21
Reg. statusRUO
0.1 mg
231.00 USD
-134%
Reg. statusCE IVD
ApplicationFC
100 ml
66.00 USD
-134%
Reg. statusRUO
ApplicationFC
100 ml
55.00 USD